All News

Post Exubera, inhaled insulin has been an uphill struggle with regulators.

Dr. Shantanu Agrawal, director of data sharing & partnership group and the medical director for the center for program integrity at CMS on the Physician Payment Sunshine Act

We are now less than three weeks away from the initial sign up period for Obamacare. After October 1st, the reality of the program and all that it portends for the future of the US pharmaceutical industry will begin to make itself apparent

Smartwatches need health data to matter, writes Peter Houston.

Already approved in 22 countries, GW Pharma’s Sativex product, if approved by FDA, would become the first prescription drug derived from raw cannabis to enter the US market.

The first 120 minutes of a crisis can determine the public’s perception of an organization. And in today’s digital world, companies are more at risk than ever to viral attacks from unexpected sources.

Since the Omnicom-Publicis merger was announced in late July, it appears the only sources that have not commented on the joining of the superpowers are the President, the Pope, and WikiLeaks.

Regulators and sponsors are seeking more productive research strategies to alleviate the squeeze in R&D investment, writes Jill Wechsler.

A key issue for biopharma marketers today is balancing cost and value factors around specialty biologic drugs, particularly those for cancer and other high profile, lifealtering diseases.

The last few weeks have seen the media swamped with stories about the rampant bribery clawing the pharmaceutical industry in China

Go to any communications seminar, forum, convention or workshop right now and the program will be populated with the latest and greatest trends in social communication platforms and how important these are if you want to be successful

On Café Pharma message boards, the drug industry’s online water cooler, anonymous sales reps are sounding off on the Physician Payment Sunshine Act and its implications for their battered profession.

Novo Nordisk’s SVP of national diabetes sales speaks with PharmExec about a new field force technology initiative, implications of the Sunshine Act, and why Victoza sales won’t slow down anytime soon.

With the pharma industry spending over $31 billion a year on product promotion, the melding of ad giants Omnicom and Publicis beckons a closer look.

A key issue for biopharma marketers today is balancing cost and value factors around specialty biologic drugs, particularly those for cancer and other high profile, life-altering diseases.

What does it take for internal Promotional Review Committees to function at their best and avoid costly mistakes to the company? A leading industry practitioner offers 15 tips for high performing teams.

Speaking at CBI’s Sunshine & Aggregate Spend Conference in Washington DC on Tuesday, Shantanu Agrawal, director, data sharing and partnership group, center for program integrity, CMS, said the agency hired IT company CGI to build the software platform to be used for publishing pharma payments to physicians under the Sunshine Act provisions, now re-branded “open payments.”

As the process to create the Transatlantic Trade and Investment Partnership (T-TIP) gets underway, Reflector asks, what is the likelihood of drug firms - and patients - reaping any rewards from the negotiations?

3bl Media

Earlier this week, the federal government’s Patient Centered Outcomes Research Institute (PCORI) unveiled a new survey, revealing that both patients and clinicians want in health research to focus on one thing: improving outcomes

Editorial Director William Looney discusses the five essential characteristics exhibited by the more than 200 men and women selected by Pharmaceutical Executive as Emerging Pharma Leaders

If you no longer had to worry about the Anti-Kickback Statute, Stark Law or the Sunshine Act, would your professional marketing strategy change? Probably, if you like making money.

As many of you may recall, earlier this year I commented on a section of the new Obamacare law that directed Members of Congress and their staffs to participate in the new healthcare program, effective January 1, 2014.

Roche tmpphis week has announced a partnership with the UN-backed Medicines Patent Pool (MPP) to provide its drug valganciclovir, better known in the developed world as Valcyte, in 138 countries for a reduced price.

We’re already embroiled in the annual speculation game about whether FDA approvals this year will keep pace with last year’s near-record of 39 new molecular entities (NMEs) brought to market

With announcements pouring in since the beginning of this year, FDA’s fourth and newest expedited approval pathway for medicines has begun to bear fruit. Established in 2012 within the FDA Safety and Innovation Act (FDASIA), Breakthrough Therapy designations have so far totaled 25 as of the end of July.

In the spirit of lawn chair cogitation and hammock-spun reverie, Pharm Exec invites you to submit your own verses-pharma-related, of course-to be published on our website in late August.

The trade media is ablaze with lurid accounts of bribery, tax fraud, and other illicit promotional activities in China-ironically, the country touted as guarantor of our industry's future.

Eight months into the launch of its first approved drug – Iclusig (ponatinib), a small molecule therapy indicated for two rare forms of leukemia – Ariad Pharmaceuticals’ principal founder and CEO Harvey Berger says doing it all, from discovery to global commercialization, is the company’s path to sustainability and the way to take on Big Pharma.

The value of retrospective studies cannot be overstated. Retrospective studies affect many healthcare sectors, including the pharmaceutical industry and general public health